Dacogen Leukemia Indication Would Require New Clinical Trial, FDA Tells Eisai
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency declined to approve decitabine for use in elderly patients with acute myelogenous leukemia because the pivotal study failed to demonstrate a statistically significant survival benefit in the pre-specified primary analysis. FDA’s “complete response” letter tracks with a negative evaluation by the Oncologic Drugs Advisory Committee in February.
You may also be interested in...
Cyclacel Continues AML Trial Of Sapacitabine Despite Futility Analysis
The oncology biotech is plowing ahead with its late-stage study of sapacitabine, despite unfavorable findings during an interim analysis.
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.